photo walkheader_zpsd5bunpmi.png

Author Archives: pancreatica


Davendra P.S. Sohal, Pamela B. Mangu, Alok A. Khorana, Manish A. Shah, Philip A. Philip, Eileen M. O’Reilly, Hope E. Uronis, Ramesh K. Ramanathan, Christopher H. Crane, Anitra Engebretson, Joseph T. Ruggiero, Mehmet S. Copur, Michelle Lau, Susan Urba and Daniel Laheru ABSTRACT Purpose: To provide evidence-based recommendations to oncologists and others for the treatment […]

Share Button

MRI Screening Protocol for Pancreatic Cancer as Surveillance for High Risk Family Members

About 10% of those diagnosed with pancreatic cancer are found to have a reasonably strong pancreatic cancer family history or that of another genetic complex or syndrome which tends to include pancreatic cancer. Consequently, many family members often ask us or their medical teams what their risks are, and what measures might be taken to […]

Share Button

“Modified” FOLFIRINOX Regimen Approved by FDA for 2nd Line Treatment of Pancreatic Cancer

On the 22nd of October, 2015, the U.S. Food and Drug Administration approved a new combination therapy that includes the drug Onivyde for patients with metastatic pancreatic cancer who had earlier been treated until progression of disease while on gemcitabine or a gemcitabine-based regimen. Onivyde is liposomal irinotecan, a topoisomerase I inhibitor (was called CPT-11, […]

Share Button